GenAssist Therapeutics is Drug Discovery in China that focus on editing technology business. Founded in 2020. They cover business area such as developer, gene, drug, global intellectual property right, TAM, neuromuscular disease, effective therapy, DMD, SMA, situ, patient, permanent cure, many human disease.
2020
( 4 years old in 2024 )
Editing Technology
-
Unit E395, North Block, A1 Building, Biomedical Industrial Park, No.218 Xinghu Street
Suzhou Industrial Park, Jiangsu Pilot Free Trade Zone
Suzhou, Jiangsu
China
Private
developergenedrugglobal intellectual property rightTAMneuromuscular diseaseeffective therapyDMDSMAsitupatientpermanent curemany human disease
* We use standard office opening hours in near GenAssist Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
GenAssist Therapeutics is Drug Discovery business from China that founded in 2020 (4 years old in 2024), GenAssist Therapeutics business is focusing on Editing Technology.
GenAssist Therapeutics headquarter office and corporate office address is located in Unit E395, North Block, A1 Building, Biomedical Industrial Park, No.218 Xinghu Street Suzhou Industrial Park, Jiangsu Pilot Free Trade Zone Suzhou, Jiangsu China.
GenAssist Therapeutics was founded in China.
In 2024, GenAssist Therapeutics is currently focus on editing technology sector.
Above is snippet of Google Trends for "editing technology" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with GenAssist Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
